No

Estrogen Derivative

Atrophic vaginitis; hypogonadism; primary ovarian failure; vasomotor symptoms of menopause; prostatic carcinoma; osteoporosis prophylactic

X

Thrombophlebitis; undiagnosed vaginal bleeding; hypersensitivity to quinestrol or any component; known or suspected pregnancy; carcinoma of the breast; estrogen-dependent tumor

>10%:

Cardiovascular: Peripheral edema

Endocrine & metabolic: Enlargement of breasts (female and male), breast tenderness

Gastrointestinal: Nausea, anorexia, bloating

1% to 10%:

Central nervous system: Headache

Endocrine & metabolic: Increased libido (female), decreased libido (male)

Gastrointestinal: Vomiting, diarrhea

No significant interactions reported

Increases the synthesis of DNA, RNA, and various proteins in target tissues; reduces the release of gonadotropin-releasing hormone from the hypothalamus; reduces FSH and LH release from the pituitary

Onset of therapeutic effect: Commonly within 3 days of treatment

Duration: Can persist for as long as 4 months

Serum half-life: 120 hours

Adults: Female: Oral: 100 mcg once daily for 7 days; followed by 100 mcg/week beginning 2 weeks after inception of treatment; may increase to 200 mcg/week if necessary

May rarely cause dizziness, anxiety, or depression

Barbiturates may decrease the effects of estrogens

No information available to require special precautions

No effects or complications reported

Patients should inform their physicians if signs or symptoms of any of the following occur: Thromboembolic or thrombotic disorders including sudden severe headache or vomiting, disturbance of vision or speech, loss of vision, numbness or weakness in an extremity, sharp or crushing chest pain, calf pain, shortness of breath, severe abdominal pain or mass, mental depression or unusual bleeding; patients should discontinue taking the medication if they suspect they are pregnant or become pregnant.

Tablet: 100 mcg